Investor Access
Please enter the password to access investor materials.
Investor Materials
Financial Overview
Revenue
$4.2M
↑ 18% YoYR&D Investment
$1.8M
↑ 25% YoYPatient Treatments
342
↑ 32% YoYClinical Success Rate
87%
↑ 5% YoYInvestor Documents
-
Q1 2025 Financial Report
Comprehensive financial analysis for the first quarter of 2025, including revenue streams, R&D expenditures, and growth projections.
Download PDF -
Clinical Trial Results - Stem Cell Therapy for Osteoarthritis
Detailed results from our Phase II clinical trials showing 87% efficacy in reducing joint pain and improving mobility.
Download PDF -
Investor Presentation - March 2025
Latest presentation outlining our business strategy, market position, and growth opportunities in regenerative medicine.
Download PDF -
Regulatory Approval Timeline
Updated timeline for FDA and international regulatory approvals for our stem cell therapies and treatments.
Download PDF
Upcoming Investor Events
-
Q2 Earnings Call
Date: April 15, 2025 | Time: 2:00 PM EST
Join our executive team for a discussion of Q2 financial results and business updates.
Add to Calendar -
Annual Shareholder Meeting
Date: May 20, 2025 | Location: Virtual
Annual meeting to discuss company performance, vote on proposals, and outline future strategy.
Registration Details